Monthly Buprenorphine Injections Support Treatment Retention

Medication-assisted treatment works when people can stay on it, and for many people leaving medical detox the hardest part is not withdrawal itself. It is what happens two weeks later, when a prescription runs out during a move, a hospital stay, or a stretch without transportation.

A review in Psychiatric Times argues that long acting injectable buprenorphine addresses exactly that failure point, and that the clinical problem is rarely a lack of willingness to be treated but the difficulty of staying in treatment.

Why Medication-Assisted Treatment Needs Continuity

Daily buprenorphine taken under the tongue is highly effective, but the review notes that everyday care is often derailed by missed doses, rural distances, transportation problems, stigma, unstable housing, pharmacy barriers, and loss of follow-up during transitions such as hospitalization, incarceration, or residential treatment.

In the fentanyl era those interruptions carry sharper consequences, including severe physiological dependence, fluctuating tolerance, and elevated overdose risk.

This is the window that medical detox alone does not close. Detox manages withdrawal. It does not by itself provide the sustained medication-assisted treatment coverage that reduces return to use.

Understanding Long Acting Buprenorphine

Buprenorphine is a partial opioid agonist with high affinity and slow dissociation at the mu opioid receptor, properties that suppress withdrawal, reduce craving, and blunt the effect of other opioids.

Long acting formulations are injected under the skin by a health care professional rather than self-administered daily, which produces sustained exposure over a clinically meaningful interval.

Development of the monthly depot formulation was guided by an exposure framework in which plasma concentrations above 2 ng/mL are associated with substantial mu receptor occupancy and meaningful opioid blockade. In practice, that steadier exposure smooths peaks and troughs and removes the daily logistics of filling and taking a prescription.

Available Options in the United States

Two long acting injectable buprenorphine products are approved in the US, Sublocade and Brixadi. Both are subcutaneous injections administered by a health care professional, both are indicated for moderate to severe opioid use disorder, and both are available only through restricted Risk Evaluation and Mitigation Strategy programs.

Sublocade is the only once-monthly formulation supporting a rapid induction approach, in which a single 4 mg dose of transmucosal buprenorphine establishes tolerance without precipitated withdrawal before the first injection, with the second injection possible as early as one week later.

Clinical studies found this approach well tolerated with higher retention through the second injection than the traditional approach requiring at least seven days of stabilization first.

Brixadi comes in weekly and monthly formulations. The two are not interchangeable milligram for milligram, and multiple weekly injections cannot be combined to equal a monthly dose.

People not currently receiving buprenorphine may begin after a 4 mg transmucosal test dose, starting on the weekly formulation before moving to monthly. People already taking transmucosal buprenorphine may transition to either, based on clinical judgment.

What the Evidence Shows

Randomized trials established that extended release buprenorphine improved opioid abstinence, treatment success, craving, and withdrawal outcomes compared with placebo, and long-term studies showed durable benefit without new major safety signals.

Participants receiving monthly injectable buprenorphine also reported improvements in health-related quality of life and medication satisfaction.

Emerging fentanyl-era data suggest sustained buprenorphine exposure can attenuate fentanyl-induced respiratory depression, and newer trials support faster initiation pathways for some higher risk patients. The review is explicit that these findings do not eliminate overdose risk, particularly when sedatives or alcohol are involved.

Finding Medical Detox

If you are looking at options, ask a prospective program three concrete questions. Does it offer medication for opioid use disorder on site or only referrals? Can it start a long acting injection before discharge? What is the specific handoff plan for the first 30 days after you leave?

Detox.com lists medically supervised detox programs by location and level of care. Call 800-996-6135(Sponsored) to find medically supervised detox programs near you.